660823-37-0

Basic information

• Product Name: 1H-Indazole-3-carboxylicacid,7-amino-,methylester(9CI)
• Synonyms: 1H-Indazole-3-carboxylicacid,7-amino-,methylester(9CI);1H-Indazole-3-carboxylic acid, 7-aMino-, Methyl ester;Methyl 7-amino-1H-indazole-3-carboxylate
• CAS NO: 660823-37-0
• Molecular Formula: C9H9N3O2
• Molecular Weight: 191.19
• Product Categories: AMINOACID
• Mol File: 660823-37-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 432.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.413±0.06 g/cm3(Predicted)
• PKA: 12.83±0.40(Predicted)
• CAS DataBase Reference: 1H-Indazole-3-carboxylicacid,7-amino-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole-3-carboxylicacid,7-amino-,methylester(9CI)(660823-37-0)
• EPA Substance Registry System: 1H-Indazole-3-carboxylicacid,7-amino-,methylester(9CI)(660823-37-0)

Safety Data

• Hazardous Substances Data: 660823-37-0(Hazardous Substances Data)

Usage

General Description

1H-Indazole-3-carboxylic acid, 7-amino-, methyl ester (9CI) is a chemical compound with the molecular formula C9H9N3O2. It is a methyl ester derivative of 1H-indazole-3-carboxylic acid, which is a heterocyclic compound with potential pharmaceutical applications. The 7-amino substituent on the indazole ring may impart biological activity, and the methyl ester group enhances the compound's lipophilicity and potential for cell permeability. 1H-Indazole-3-carboxylicacid,7-amino-,methylester(9CI) may have potential as a drug lead or pharmacological tool in the development of new medicines for various therapeutic applications. Additionally, it may also serve as a valuable intermediate in organic synthesis for the preparation of other related compounds.

Upstream product

• 1360893-27-1 7-nitro-1H-indazole-3-carboxylic acid methyl ester 
• 78155-75-6 methyl 5-nitro-1H-indazole-3-carboxylate 

Relevant articles and documents

1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS

The invention provides compounds of the formula: (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a MAPKAP kinase: wherein A is a bond or a group CH2; R1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; R3, R4, R5 and R6 are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra -Rbwherein Ra is a bond, 0, CO, X1C(X2), C(X2)Xl, X1C(X2)X1, S, SO, S02, NRc, SO2NRc or NRcS02; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by 0, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; Rc is hydrogen or C1-4hydrocarbyl; and X1 is O, S or NRc and X2 is =O, =S or =NRc.